STOCK TITAN

Elite Health Systems (EHSI) adds $525K subordinated note, CEO warrants

(High)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Elite Health Systems Inc. entered into a financing with its CEO, Dr. Prasad Jeereddi, consisting of a $525,000 subordinated note and an accompanying warrant. The note is unsecured, bears 10% annual interest, includes a 2% prepayment penalty, and matures on July 31, 2027.

The warrant allows Dr. Jeereddi to purchase up to 110,526 shares of common stock at $0.95 per share, exercisable in whole or part through July 31, 2031, including on a cashless basis if the shares are not then registered. These warrant shares are currently unregistered and subject to transfer restrictions. The agreement permits additional investment on the same terms up to an aggregate of $1.5 million.

Positive

  • None.

Negative

  • None.
Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Subordinated Note Principal $525,000 Principal amount of the subordinated note with the CEO
Note Interest Rate 10% per annum Annual interest rate on the subordinated note
Prepayment Penalty 2% Penalty applied to prepayment of the note
Note Maturity Date July 31, 2027 Maturity date of the subordinated note
Warrant Shares 110,526 shares Maximum number of common shares purchasable under the warrant
Warrant Exercise Price $0.95 per share Exercise price for shares under the warrant
Warrant Expiration July 31, 2031 Final exercise date for the warrant
Aggregate Investment Capacity $1.5 million Maximum aggregate investment permitted on the same terms
subordinated note financial
"approved entering into a $525,000 subordinated note and warrant agreement"
A subordinated note is a loan-like security a company issues that ranks below its other debts when paying creditors; if the company runs into trouble, holders of subordinated notes are repaid only after senior lenders. Because they are lower in the repayment order, these notes typically offer higher interest to compensate for greater risk, so investors balance the chance of higher returns against a higher likelihood of loss in distress—like taking a back-seat on a bus with a bigger fare.
warrant agreement financial
"entered into a warrant agreement with Dr. Jeereddi to purchase shares"
A warrant agreement is the legal document that lays out the rules for stock warrants — special certificates that let their holder buy company shares at a set price within a certain time. It explains how and when warrants can be exercised, transferred, changed, or canceled, and what happens to them if the company raises money or is sold; investors care because these terms affect potential future ownership, dilution of shares, and the real value of the warrants.
cashless basis financial
"may be exercised ... on a cashless basis in the event the shares are not registered"
An agreement executed on a cashless basis lets a holder convert or exercise a security (like options, warrants, or conversion rights) without paying money upfront; instead the holder receives a smaller number of shares equal in value to what the cash would have purchased. Think of trading a coupon for fewer slices of a cake rather than handing over cash for the full slice. For investors, it affects how much ownership and dilution occur and avoids immediate cash outlays.
restrictions on transfer financial
"Shares issuable pursuant to the warrant are not currently registered and accordingly carry certain restrictions on transfer"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What financing did Elite Health Systems (EHSI) approve on July 31, 2026?

Elite Health Systems approved a $525,000 subordinated note and related warrant with its CEO, Dr. Prasad Jeereddi. The note is unsecured, carries 10% annual interest, and matures on July 31, 2027, forming part of a broader potential $1.5 million facility.

What are the key terms of EHSI’s subordinated note with its CEO?

The note has a principal amount of $525,000, is unsecured, and bears 10% interest per year. It is due on July 31, 2027 and includes a 2% prepayment penalty, with the instrument subordinated to other obligations as described.

What warrant rights were granted by Elite Health Systems (EHSI)?

Elite Health Systems issued a warrant for up to 110,526 shares of common stock at an exercise price of $0.95 per share. The warrant is exercisable in whole or in part through July 31, 2031, including on a cashless basis under specified registration conditions.

Are the warrant shares issued by EHSI to its CEO currently registered?

No, the shares underlying the warrant are not currently registered and therefore carry restrictions on transfer. The warrant also allows cashless exercise if the shares are unregistered at the time of exercise, affecting how the CEO may realize value.

How much additional capital can Elite Health Systems (EHSI) raise on these terms?

The note agreement allows Elite Health Systems to accept additional investment on the same terms up to an aggregate of $1.5 million. The disclosed $525,000 tranche is part of this capacity, leaving room for further similar financings if pursued.
false 0001089815 0001089815 2026-07-31 2026-07-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): July 31, 2026
 
Elite Health Systems Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
000-26575
52-1842411
(State of other jurisdiction of 
(Commission
(I.R.S. Employer
incorporation or organization)  
File Number)
Identification No.)
 
1131 W 6th Street
 
 
OntarioCA
 
91762
(Address of principal executive offices)
 
(Zip Code)
 
Registrant's telephone number, including area code:
(949249-1170
 
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act: N/A
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company                     
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.         ☐
 

 
Item 1.01. Entry onto a Material Agreement.
 
On July 31, 2026, the independent members of the board of directors of Elite Health Systems Inc. (the “Registrant”) approved entering into a $525,000 subordinated note and warrant agreement (the “Note Agreement”) with Dr. Prasad Jeereddi, the Company’s CEO and chair. The note is due on July 31, 2027, is unsecured, carries an interest rate of 10% per annum and includes a 2% prepayment penalty.
 
The Company simultaneously entered into a warrant agreement with Dr. Jeereddi to purchase up to 110,526 shares of the Company’s common stock at an exercise price of $0.95 per share through the maturity date of July 31, 2031. The warrant may be exercised in whole or in part at any time up to the maturity date, including on a cashless basis in the event the shares issuable pursuant to the warrant are not registered at the point of exercise. Shares issuable pursuant to the warrant are not currently registered and accordingly carry certain restrictions on transfer.
 
The Note Agreement provides that the Registrant may accept additional investment, on the same terms, of up to an aggregate of $1.5 million.
 
 
 
Item 9.01. Financial Statements and Exhibits.
 
(d)
Exhibits
 
10.1
Senior Unsecured Promissory Note with Dr. Prasad Jeereddi
 
10.2
Warrant Agreement between the Company and Dr. Prasad Jeereddi
 
 
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
2

 
EXHIBIT LIST
 
 
Number
Description         
 
10.1
Senior Unsecured Promissory Note with Dr. Prasad Jeereddi
 
10.2
Warrant Agreement between the Company and Dr. Prasad Jeereddi
 
 
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
3

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Date: August 5, 2026
 
 
 
 
Elite Health Systems Inc.
 
 
 
 
By:
/s/ Kenneth Minor
 
Name:
Kenneth Minor
 
Title:
Chief Financial Officer
 
4

Filing Exhibits & Attachments

6 documents